Fulcrum Therapeutics
FULC
39 hedge funds and large institutions have $105M invested in Fulcrum Therapeutics in 2019 Q3 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
68.15% more ownership
Funds ownership: 0% → 68.15% (+68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
+$66M |
| 2 |
TGI
TRV GP IV
Boston,
Massachusetts
|
+$25.9M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$18.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.5M |
| 5 |
CC
Casdin Capital
New York
|
+$9.34M |
Top Sellers
FULC Hedge Fund Activity: Q3 2019 in Review
39 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2019, worth a combined $105M.
Buyers outnumbered sellers: 39 funds opened new FULC positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TRV GP III, opening a new position worth an estimated $66M.
- 39 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2019, up from 0 in Q2 2019.
- Funds reported $105M of Fulcrum Therapeutics stock for Q3 2019.
- 39 funds opened new Fulcrum Therapeutics positions in Q3 2019 and 0 closed out, a net change of +39 holders.
- The largest Fulcrum Therapeutics buyer in Q3 2019 was TRV GP III, an estimated $66M added.
Based on aggregated 13F filings for Q3 2019.